Skip to main content

Market Overview

Pfizer's Lorbrena Wins Full FDA Approval As First Line Treatment Of ALK-Positive Lung Cancer


The FDA has approved Pfizer Inc's (NYSE: PFE) supplemental application seeking approval for Lorbrena (lorlatinib), expanding the indication to include first-line treatment of people with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC).

  • The FDA action also converts 2018 accelerated approval to full approval.
  • In 2018 Lorbrena was approved for patients with ALK-positive metastatic NSCLC whose disease has progressed on crizotinib and at least one other ALK inhibitor; or whose disease has progressed on alectinib or ceritinib as the first ALK inhibitor therapy.
  • The approval is based on the CROWN trial, which showed a 72% reduction in risk of progression or death for treatment with Lorbrena vs. Xalkori, recognized as the first-line standard of care for patients with ALK-positive advanced NSCLC.
  • Price Action: PFE shares are down 0.4% at $34.25 in premarket trading on the last check Thursday.

Related Articles (PFE)

View Comments and Join the Discussion!

Posted-In: Non-Small Cell Lung CancerBiotech News Health Care FDA General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at